Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessWhy Did The Vanguard Group Inc. Increased Its Shares To Almost $6...

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX

silver-background-3 (14) (2)

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com

Institutional investors currently hold major shares in  BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

BioPharmX Corporation  (BPMX)  stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume.

Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025.

Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 billion British pounds

Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
VIVO CAPITAL, LLC 05/13/2018 16,128,515 2,328,571 16.87 3,306
FRANKLIN RESOURCES INC 05/13/2018 9,749,615 0 0.00 1,999
VANGUARD GROUP INC 05/13/2018 5,498,918 3,541,971 181.00 1,127
GEODE CAPITAL MANAGEMENT, LLC 03/31/2018 671,686 347,719 107.33 138
VIRTU FINANCIAL LLC 03/31/2018 426,837 426,837 New 88
BARCLAYS PLC 03/31/2018 362,900 362,900 New 74
SUSQUEHANNA INTERNATIONAL GROUP, LLP 03/31/2018 181,335 181,335 New 37
CITADEL ADVISORS LLC 03/31/2018 146,859 146,859 New 30
MCF ADVISORS LLC 03/31/2018 105,629 105,629 New 22
JANE STREET GROUP, LLC 03/31/2018 96,941 96,941 New 20
TWO SIGMA SECURITIES, LLC 03/31/2018 93,390 47,105 101.77 19
NORTHERN TRUST CORP 03/31/2018 92,518 0 0.00 19
UBS GROUP AG 03/31/2018 70,367 36,614 108.48 14
LADENBURG THALMANN FINANCIAL SERVICES INC. 03/31/2018 64,200 0 0.00 13
CREDIT SUISSE AG/ 03/31/2018 50,000 50,000 New 10
HOLDERS SHARES
Increased Positions 17 7,708,826
Held Positions 7 15,447,095
Total Institutional Shares 27 33,878,519

On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million.

For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million.

BioPharmX Corporation  (BPMX) has been working on the following pipeline for new products and FDA approvals.

HYDROPHILIC TOPICAL SYSTEM

1 Patent Issued, 21 Pending

STABILIZES

  • Hydrophilic: non-occlusive, non-oily
  • Non-lipophilic (oil-based)
  • Suitable for APIs degraded in water

FULLY SOLUBILIZES

  • Improves bioavailability
  • Not a suspension
  • Miscible w/ sebum

Higher penetration and targeted delivery

THERAPEUTICS

BPX-01-Acne

BPX-04-Rosacea

BPX-Retinoids

BPX-Combinations

INJECTABLE SYSTEM

1 Patent Pending

CROSSLINKED

  • Proprietary cross-linked injectable delivery system

SUSTAINED RELEASE

  • Prolonged release of biologics and small to mid-sized molecules

Suitable for aesthetics

AESTHETICS

BPX-02

ENCAPSULATION SYSTEM

3 Patents Issued, 4 Pending

ISOLATES

  • Separates hydrophilic APIs from boundary layer

ENCAPSULATES

  • Encapsulates between the hydrophilic and hydrophobic phases of emulsion

Emulsion feels smooth to the touch

COSMETICS

IODINE SYSTEM

1 Patent Allowed, 3 Pending

STABILIZES

  • Oral delivery of iodide and iodate
  • Patented formulation stabilizes iodine

TARGETS

  • Delivery to targeted mammary cells
  • Apoptotic and anti-proliferative effects

Commercially available product since 2014

WOMEN’S HEALTH

BPX-03

Women’s Health Asset for Strategic Partnerships

The patent (U.S. Patent No. 9,918,998), entitled “Pharmaceutical Tetracycline Composition For Dermatological Use,” covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.

This is the fourth U.S. patent issuance BioPharmX (BPMX) has received. Three earlier-issued U.S. patents protect the company’s encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled “Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers,” was granted Feb. 27.

The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX’s innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.

“This patent protection is a significant milestone for BioPharmX,” said President and Co-founder Anja Krammer. “It recognizes that our development of a topical tetracycline-class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique.”

BioPharmX has successfully completed a phase 2b trial for BPX-01 for acne and is in phase 3 readiness. The company has reported positive interim results from a feasibility study for BPX-04 for rosacea and is preparing for a phase 2 trial.

Anthony Vendetti  from Maxim Group maintained a  Buy  rating on BioPharmX Corp (NYSE:  BPMX), with a price target of  $1.50.

The Industry Biotechnology & Medical Research also suggest that    BioPharmX Corporation  (BPMX) is currently the cheapest stock against major companies below:

PTIE Pain Therapeutics Inc Com New 4/23/18 10.15 30.46%
SNMX Senomyx Inc Com 5/14/18 1.42 8.40%
VRTX Vertex Pharmaceuticals Inc Com 5/13/18 157.24 0.81%
ARQL Arqule Inc Com 5/18/18 3.39 0.00%
ICLR Icon Plc Shs 5/21/18 125.74 0.00%

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that  BioPharmX Corporation  (BPMX)  , is undervalued.    

CWEB Analysts have Reiterate a Buy Rating for  BioPharmX Corporation  (BPMX)    and a Price Target of $7 within 12 months.

A possible partnership or major investment for    BioPharmX Corporation  (BPMX)    is strongly possible in this coming month by big pharmaceutical company.

Read Full Article and Videos  CWEB.com – Trending News, Blog, Shopping

Chart
BPMX  data by  YCharts

 

[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Google code on Pinterest app suggests potential test of ad units, CWEB analysts say

Google and Pinterest might be testing a new partnership....

DraftKings Falls, NCAA Wants to Ban College Prop Bets. CWEB analysts issue Hold Rating on the stock.

Shares of DraftKings Inc.(DKNG) experienced a significant decline on...

Chick-Fil-A backtracks on NAE pledge, to use some antibiotics in chicken

Chick-Fil-A backtracked on its No Antibiotics Ever (NAE) policy...

Bloom Energy’s Price Target Cut at Susquehanna

Susquehanna analysts adjusted their price target for Bloom Energy...